Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hikma 'sixth largest US generics firm' following Roxane buy from Boehringer

This article was originally published in Scrip

Executive Summary

Hot on the heels of Teva's acquisition of Allergan's generics business, Hikma Pharmaceuticals has agreed to buy US generics firm Roxane Laboratories from Boehringer Ingelheim in a deal worth around $2.65bn, making Hikma "the sixth largest generics company" by revenue in the US. "The US generics market is currently a very attractive place to be," Hikma's CEO Said Darwazah told Scrip. "If you want to grow fast, there is no other market that can provide you with this kind of opportunity."



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts